Systemic Diseases and Ageing
PRINCIPAL INVESTIGATORS
- Francesc Formiga Perez
- Ramon Lleonart Bellfill
- Xavier Solanich Moreno
CLINICAL RESEARCHERS
- Olga Capdevila Pons
- David Chivite Guillen
- Manuel Rubio Rivas
- Ferran Bolao Baro
- Abelardo Montero Saez
- Francesca Mitjavila Villero
- Jose Maria Mora Luján
- Paula Vazquez Revuelta
PREDOCTORAL RESEARCHERS
- Adriana Iriarte Fuster
- Pau Cerdà Serra
- Gemma Rocamora Blanch
Translational Medicine
Cardiovascular, Respiratory and Systemic Diseases and cellular aging
Scientific production
68
PAPERS
Impact factor: 295,55
8 PUBLICATIONS IN FIRST DECILE
37 PUBLICATIONS IN FIRST QUARTILE
39 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Rubio Rivas M, Corbella X, Guillén Castillo A, Tolosa Vilella C, Colunga Argüelles D, Argibay A, Vargas Hitos JA, Todolí Parra JA, González Echávarri C, Ortego Centeno N, Trapiella Martínez L, Rodríguez Carballeira M, Marín Ballvé A, Pla Salas X, Perales Fraile I, Chamorro AJ, Madroñero Vuelta AB, Freire M, Ruiz Muñoz M, González García A, Pons Martín Del Campo I, Sánchez García ME, Bernal Bello D, Espinosa G, García Hernández FJ, Sáez Comet L, Ríos Blanco JJ, Fernández de la Puebla Giménez RÁ, Sánchez Trigo S, Fonollosa Pla V, Simeón Aznar CP, RESCLE I, Autoimmune Diseases Study Group (. Corrigendum to ‘Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation’ [AUTREV 19-5 (2020) 102507]. AUTOIMMUN REV. 2021;20(5):102793-102793. doi:10.1016/j.autrev.2021.102793. IF:9,75.
- Rubio Rivas M, Homs NA, Cuartero D, Corbella X. The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: Systematic review and meta-analysis. AUTOIMMUN REV. 2021;20(1):102713-102713. doi:10.1016/j.autrev.2020.102713. IF:9,75.
- Riera Mestre A, Iriarte A, Moreno M, del Castillo R, Lopez Wolf D. Angiogenesis, hereditary hemorrhagic telangiectasia and COVID-19. Angiogenesis. 2021;24(1):13-15. doi:10.1007/s10456-020-09755-5. IF:9,60.
- Solanich X, Rigo Bonnin R, Gumucio VD, Bastard P, Rosain J, Philippot Q, Perez Fernandez XL, Fuset Cabanes MP, Gordillo Benitez MÁ, Suarez Cuartin G, Boza Hernandez E, Riera Mestre A, Parra Martínez A, Colobran R, Antolí A, Navarro S, Rocamora Blanch G, Framil M, Calatayud L, Corbella X, Casanova JL, Morandeira F, Sabater Riera J. Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona. J. Clin. Immunol. 2021;41(8):1-12. doi:10.1007/s10875-021-01136-x. IF:8,32.
- Pestana Fernandez M, Rubio Rivas M, Tolosa Vilella C, Guillen Castillo A, Colunga Arguelles D, Argibay A, Mari Alfonso B, Marin Ballve A, Pla Salas X, Chamorro AJ, Castro Salomo A, Madronero Vuelta AB, Sanchez Garcia ME, Saez Comet L, Gonzalez Echavarri C, Ortego Centeno N, Vargas Hitos JA, Todoli Parra JA, Trapiella Martinez L, Lledo GM, Freire M, Fonollosa Pla V, Simeon Aznar CP, RESCLE I, Autoimmune Dis Study GEAS GRP. The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i). Rheumatology (Oxford). 2021;60(2):872-880. doi:10.1093/rheumatology/keaa401. IF:7,58.
Research highlights
PROJECTS
5 Competitive projects
14 Non competitive projects
21 Clinical trials
PUBLISHED WORKS
2 Theses
3 Clinical Guidelines
NETWORKS
COVID-HGE
RIETE
RiHHTa
Selected projects
- MAR21015. Role of immune system inborn errors as determinants of the COVID-19 severity in hospitalized patients. (202115-31). FUNDACIO IDIBELL; FUNDACIÓ LA MARATÓ DE TV3; INSTITUT CATALA DE LA SALUT (ICS). Importe Concedido:128.123,85€. 2021-2024. IP:SOLANICH MORENO,XAVIER.
- 21FIS010. Nuevas vías de señalización clínicamente relevantes relacionadas con la Telangiectasia Hemorrágica Hereditaria. (PI20/00592). ISCIII. Importe Concedido:182.710,00€. 2021-2023. IP:RIERA MESTRE,ANTONI.
- 18NOF010. Grup de Recerca en Malalties Sistèmiques i Envelliment, pertanyent a l’Àrea de recerca número 5: Malalties Inflamatòries, Cròniques i Degeneratives. (2017SGR916). DIR.GEN.SALUT PUBLICA, DEP.SALUT GE. 2018-2021. IP:RIERA MESTRE,ANTONI.
- 18FIS008. Estudio de alteraciones en vías de señalización del endotelio vascular y su correlación clínica en la Telangiectasia Hemorrágica Hereditaria. Importe Concedido:87.120,00€. 2018-2021. IP:RIERA MESTRE,ANTONI.
- CEE21011. COVend: Biomarker and AI-supported FX06 therapy to prevent progression from mild and moderate to severe stages of COVID-19. (101045956). COMISSIÓ EUROPEA. 2021-2024. IP:RIERA MESTRE,ANTONI.